The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation

Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F, the role of JAK inhibitors in post-PV MF patients with JAK2 exon 12 mutations remains unkno...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Kazuhiko, Ueda, Koki, Sano, Takahiro, Ogawa, Kazuei, Ikezoe, Takayuki, Hashimoto, Yuko, Morishita, Soji, Komatsu, Norio, Ohto, Hitoshi, Takeishi, Yasuchika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519475/
https://www.ncbi.nlm.nih.gov/pubmed/28674362
http://dx.doi.org/10.2169/internalmedicine.56.7871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519475/
https://www.ncbi.nlm.nih.gov/pubmed/28674362
http://dx.doi.org/10.2169/internalmedicine.56.7871

Ejemplares similares